NIAID considering funding smaller, intermediate trials to evaluate HIV vaccine candidates.
NIAID CONSIDERING INTERMEDIATE TRIAL CONCEPT TO EVALUATE HIV VACCINE CANDIDATES in a smaller, less time-consuming fashion prior to moving them into Phase III, National Institute of Allergy & Infectious Diseases Division of AIDS Director Jack Killen, MD, said at the June 6 AIDS Research Advisory Committee meeting. The approach, termed the "intermediate trial," would consist of a "trial that's smaller, less costly and more manageable than a pivotal trial required for licensure of a vaccine," explained NIAID's Patricia Fast.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth